Literature DB >> 14759968

Proxy identification: a time-dependent analysis.

David W Wright1, Robert Todd Lancaster, Jonathan J Ratcliff, Douglas W Lowery, Marlena M Wald.   

Abstract

OBJECTIVES: To describe the availability of next-of-kin (NOK) for proxy consent over the 24-hour time period following presentation of major trauma patients to a Level I trauma center.
METHODS: The study was conducted by using a prospective, observational study design. Consecutive patients meeting predefined major trauma criteria during a three-month study period were enrolled and followed until NOK were contacted, or up to 24 hours. Survival analysis was used to determine the probability of NOK contact during the 24-hour follow-up period.
RESULTS: Three hundred fifty (92%) of 382 subjects had NOK contacted during the follow-up period. The probabilities (95% confidence intervals [CIs]) of NOK contact at the time of arrival (t = 0) and 2, 4, 6, and 24 hours postpresentation were 0.25 (95% CI = 0.21 to 0.30), 0.68 (95% CI = 0.63 to 0.72), 0.77 (95% CI = 0.73 to 0.82), 0.80 (95% CI = 0.76 to 0.84), and 0.87 (95% CI = 0.84 to 0.90), respectively. The median time to contact was 40 minutes (95% CI = 27 to 54 min).
CONCLUSIONS: One third of the trauma patients in this study did not have NOK available two hours following arrival in the emergency department. For time-critical research protocols, the time to NOK contact can significantly impact the ability to ensure prompt enrollment and treatment in clinical trials. Further studies are needed to assess the generalizability and consistency of these data.

Entities:  

Mesh:

Year:  2004        PMID: 14759968

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  1 in total

1.  Recommendations in relation to the EU clinical trials directive and medical research involving incapacitated adults.

Authors:  Kathleen Liddell; Erwin J O Kompanje; François Lemaire; Bozidar Vrhovac; David K Menon; Julian Bion; Douglas Chamberlain; Christian J Wiedermann; Christiane Druml
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.